This is a working overview of TB-500, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-07. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
cleavage furrow A trough-like indentation in the surface of the parent cell, often conspicuous when viewed through a microscope, that initiates the cleavage of the cytoplasm (cytokinesis) as the contractile ring begins to narrow during cell division.
The Hungarian Revolution of 1956 was a spontaneous nationwide revolt by democratic socialists against the Marxist–Leninist government of the People's Republic of Hungary and its policies of repression, lasting from 23 October until 10 November 1956. Soviet leader Nikita Khrushchev's denunciation of the excesses of Stalin's regime during the 20th Congress of the Communist Party of the Soviet Union that same year as well as the revolt in Hungary produced ideological fractures and disagreements within the democratic communist and socialist parties of Western Europe. A split ensued within the Italian Communist Party (PCI), with most ordinary members and the PCI leadership, including Giorgio Napolitano and Palmiro Togliatti, regarding the Hungarian insurgents as counter-revolutionaries as reported in l'Unità, the official PCI newspaper. Giuseppe Di Vittorio, General Secretary of the Italian General Confederation of Labour, repudiated the leadership position, as did the prominent party members Loris Fortuna, Antonio Giolitti and many other influential communist intellectuals who later were expelled or left the party. Pietro Nenni, the national secretary of the Italian Socialist Party, a close ally of the PCI, opposed the Soviet intervention as well. Napolitano, elected in 2006 as President of the Italian Republic, wrote in his 2005 political autobiography that he regretted his justification of Soviet action in Hungary and that at the time he believed in party unity and the international leadership of Soviet communism.
The physical examination is the examination of the patient for medical signs of disease that are objective and observable, in contrast to symptoms that are volunteered by the patient and are not necessarily objectively observable. The healthcare provider uses sight, hearing, touch, and sometimes smell (e.g., in infection, uremia, diabetic ketoacidosis). Four actions are the basis of physical examination: inspection, palpation (feel), percussion (tap to determine resonance characteristics), and auscultation (listen), generally in that order, although auscultation occurs prior to percussion and palpation for abdominal assessments. The clinical examination involves the study of:
Octreotide, sold under the brand name Sandostatin among others, is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. It was first synthesized in 1979 and binds predominantly to the somatostatin receptors SSTR2 and SSTR5. It was approved for use in the United States in 1988. Octreotide was approved for medical use in the European Union in 2022. As of June 2020, octreotide is the first oral somatostatin analog (SSA) approved by the FDA. It is on the World Health Organization's List of Essential Medicines.
Sources: en.wikipedia.org
=== Removal and recovery of polar organics from aqueous streams === Some of King's research has dealt with the removal and recovery of polar organic substances from aqueous streams in two contexts. Research on removal of pollutants by solvent extraction was supported by the U. S. Environmental Protection Agency. He later turned to the use of solvent extraction and adsorption, with and without chemical complexation, for recovery of carboxylic acids, glycols and alcohols from aqueous process streams, such as occur in the manufacture of these chemicals from biomass by fermentation. Much of this work also dealt with novel methods of regeneration of the extractants or adsorbents. The research was sponsored by the U. S. Department of Energy through the Lawrence Berkeley National Laboratory.
Photobiology is the scientific study of the beneficial and harmful interactions of non-ionizing radiation in living organisms, conventionally demarcated around 10 eV, the first ionization energy of oxygen. UV ranges roughly from 3 to 30 eV in energy. Hence photobiology entertains some, but not all, of the UV spectrum.
Other serotonin receptors may also be involved. As such, numerous serotonin receptors appear to be involved in the regulation of oxytocin secretion. Alcohol and γ-hydroxybutyrate (GHB), though producing acute anxiolytic and prosocial effects, do not affect oxytocin levels in humans. Naturally, exogenous oxytocin increases oxytocin levels in humans. Single 16 to 40 IU doses of oxytocin increased oxytocin levels, with a peak of about 2- to 3-fold, albeit with a very short duration of around 1 to 1.5 hours. However, salivary oxytocin levels may remain elevated for longer, for instance more than 2 to 7 hours, though it is unclear that salivary oxytocin levels are a useful marker of oxytocin exposure. There is no correlation of circulating oxytocin with oxytocin in cerebrospinal fluid (CSF) with intranasal oxytocin administration and levels of oxytocin in CSF do not start to increase until 75 minutes post-administration.
=== In the military === A buzz cut or completely shaven haircut is common in military organizations where, among other reasons, it is considered to promote uniformity and neatness. Most militaries have occupational safety and health policies that govern the hair length and hairstyles permitted; in the field and living in close-quarter environments where bathing and sanitation can be difficult, soldiers can be susceptible to parasite infestation such as head lice, that are more easily propagated with long and unkempt hair. It also requires less maintenance in the field and in adverse weather it dries more quickly. Short hair is also less likely to cause severe burns from flash flame exposure (as a result of flash fires from explosions) which can easily set hair alight. Short hair can also minimize interference with safety equipment and fittings attached to the head, such as combat helmets and NBC suits. Militaries may also require men to maintain clean-shaven faces as facial hair can prevent an air-tight seal between the face and military gas masks or other respiratory equipment, such as a pilot's oxygen mask, or full-face diving mask. The process of testing whether a mask adequately fits the face is known as a "respirator fit test". In many militaries, head-shaving (known as the induction cut) is mandatory for men when beginning their recruit training.
FDA states that 798 of the 1,130 MDRs for BIA-ALCL involved textured breast implants, 37 MDRs involved smooth-surfaced implants, and 295 MDRs did not specify whether the implants were textured or smooth. In some cases, the women who developed BIA-ALCL after smooth breast implants had textured expanders prior to their implants. Most patients had BIA-ALCL affect only one breast with only 8 patients diagnosed with bilateral BIA-ALCL. The most common reported symptom of BIA-ALCL according to the FDA was seroma, followed by breast swelling and pain, capsular contracture, and peri-implant mass or lump. Furthermore, 84 percent of the reported implants were made by Allergan, the largest breast implant manufacturer at the time. A study conducted at Memorial Sloan Kettering cancer center of women undergoing prophylactic mastectomies indicated that 1 in 355 women were subsequently diagnosed with BIA-ALCL. Almost all those women had Allergan biocell implants and expanders. These reports strongly suggest that BIA-ALCL develops primarily in patients with textured implants or expanders. In all cases, however, many researchers suspect that BIA-ALCL is an under-recognized, misdiagnosed, and under-reported complication of breast implants. The ASPS and the Plastic Surgery Foundation (PSF) have partnered with the FDA to study this condition and in doing so created the Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma Etiology and Epidemiology (PROFILE).
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.